Immunotherapy targeting the CD47-SIRPα axis to promote immune clearance of chronic infection
Immunotherapy targeting the CD47-SIRPα axis to promote immune clearance of chronic infection
批准号:
9123979
负责人:
Michal Caspi Tal
金额:
$5.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-04-01 至 2017-08-31
关键词:
ApoptosisBindingCD47 geneCD8B1 geneCell physiologyCellsChronicCommunicable DiseasesHIVHIV InfectionsHighly Active Antiretroviral TherapyHumanITIMImmuneImmune responseImmune systemImmunotherapyIn VitroIndividualInfectionInhibitory SynapseLeadLigandsMediatingMediator of activation proteinModelingMusNR0B2 geneNatural Killer CellsPDCD1LG1 genePTPN11 genePatientsPersonsPhagocytesPhagocytosisProteinsReagentSHPS-1 proteinSamplingSignal PathwaySignal TransductionSurfaceT-LymphocyteTestingTherapeuticTherapeutic EffectUp-RegulationViralVirus Diseasesabstractingcancer cellexhaustexhaustionfunctional restorationimmune clearancein vivoinhibitor/antagonistkillingsmacrophagemouse modelnovelnovel markeroverexpressionpreclinical efficacypreventpublic health relevancereceptorresearch studyresponsetherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The Weissman lab has discovered that cancer cells evade clearance by the immune system through increased expression of CD47, a surface molecule that binds to the inhibitory receptor called signal-regulatory protein alpha (SIRPα) on phagocytic cells, thereby inhibiting phagocytosis. I have found that persistently infected cells in
a variety of infectious diseases also upregulate CD47 expression. Furthermore, I discovered that T cells upregulate SIRPα in response to prolonged activation, and together with collaborators have confirmed this in two distinct chronic viral infections. Most strikingly, T cell that upregulate SIRPα also have high expression levels of programmed cell death 1 (PD-1), a mediator of exhaustion. I hypothesize that the CD47-SIRPα axis is an immunomodulatory axis, whereby overexpression of CD47 in infected cells triggers SIRPα mediated blockade of both innate and adaptive immune clearance. This makes the CD47- SIRPα interaction an important target for novel immunotherapies. To this end we have developed multiple reagents to block this interaction, which we will test in vivo in mouse models of chronic infection as well as with human in vitro and patient ex vivo models. I will expand my exploration of SIRPα as a novel marker of T cell exhaustion to determine whether SIRPα is upregulated on exhausted human T cells from HIV infected individuals. I will also investigate the function of SIRPα on T cells. Concurrently w will test whether therapeutic blockade of SIRPα signaling, either alone or in combination with additional inhibitors of T cell exhaustion, can restore functionality of exhausted T cells or lead o clearance of the persistent infection. If successful the proposed experiments will demonstrate the preclinical efficacy of CD47 blockade in infectious diseases, identify a novel marker of T cell
exhaustion, and specifically test if targeting the CD47- SIRPα axis can restore functionality to exhausted T cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Unlocking serology’s secrets: harnessing novel immune biomarkers to predict Lyme disease progression and recovery
-
批准号:10737313
-
项目类别:
-
资助金额:$63.6万
-
财政年份:2023
-
负责人:Michal Caspi Tal
-
依托单位:
A role for autophagy in increased cytosolic viral signaling in aging
-
批准号:8197961
-
项目类别:
-
资助金额:$2.66万
-
财政年份:2010
-
负责人:Michal Caspi Tal
-
依托单位:
A role for autophagy in increased cytosolic viral signaling in aging
-
批准号:8060119
-
项目类别:
-
资助金额:$2.61万
-
财政年份:2010
-
负责人:Michal Caspi Tal
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: